Remicade (infliximab) (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023

◆상품코드 : GDHC494DFR
◆발행일 : 31-Dec-2014
◆페이지수 : 67
◆보고서 형식 : PDF / 영문
◆납품 방식 : Email
◆조사대상 지역 : Global
◆산업분야 : Pharmaceuticals and Healthcare
◆발행회사(조사회사) : GlobalData
◆판매회사 : H&I글로벌리서치(주)
◆판매가격 옵션
Single User Price¥394,935 -> 환산 ₩3,949,350견적의뢰/구매/질문FORM
Site License Price¥789,870 -> 환산 ₩7,898,700견적의뢰/구매/질문FORM
Enterprisewide Price (Global Site License)¥1,184,805 -> 환산 ₩11,848,050견적의뢰/구매/질문FORM
※지불하실 금액은 상기금액이며, 세금 및 배송료는 없습니다.
※지불은 선불결제 방식이며, 신용카드결제 또는 계좌입금(국내/해외)이 선택가능합니다.
※구매의사를 FORM기입 또는 E메일로 연락주시면 담당자가 회신 드리겠습니다.
※배송은 입금 확인 후, E메일로 납품드리며, 일반적으로 당일~2일정도 소요됩니다.
※가격옵션 설명 : (Single User : 귀사내에서 1명만 사용가능 / Five User, Multi User : 귀사내에서 5명까지 사용가능 / Site License, Corporate License : 동일국내에서 인원제한없이 사용가능 / Global Site License, Enterprise License : 지역상관없이 인원제한없이 사용/공유 가능한 라이센스). 자세한 설명은 이용안내 페이지를 참고하세요.


[조사보고서 개요]

Remicade (infliximab) (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023

Summary

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

Remicade (infliximab) was originally developed as a result of a collaboration between two professors at NYU Langone Medical Center and Centocor Ortho Biotech (acquired by Janssen Biotech, a subsidiary of J&J) (NYU Langone Medical Center, press release, August 12, 2005). It is first-generation TNF inhibitor consisting of a chimeric IgG1 mAb that is specific for TNFa. Remicade binds to TNFa with high affinity, neutralizing the effects of this cytokine, thus preventing synovial inflammation and decreasing joint erosion in patients with RA.

Scope

- Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Remicade (infliximab) including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Remicade (infliximab) for the top 10 countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia, China and India.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Remicade (infliximab) performance.
- Obtain sales forecast for Remicade (infliximab) from 2013-2023 in top 10 countries (the US, France, Germany, Italy, Spain, the UK and Japan, Australia, China and India).

[조사보고서 목차]

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 13
3 Disease Overview 14
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 14
3.2 Symptoms 19
3.3 Prognosis 20
3.4 Quality of Life 20
4 Disease Management 21
4.1 Diagnosis and Treatment Overview 21
4.1.1 Diagnosis 21
4.1.2 Treatment Guidelines 23
4.1.3 Leading Prescribed Drugs for the Treatment of RA 33
4.1.4 Clinical Practice 34
5 Competitive Assessment 40
5.1 Overview 40
6 Remicade (infliximab) 42
6.1 Overview 42
6.2 Efficacy 44
6.3 Safety 46
6.4 SWOT Analysis 47
6.5 Forecast 47
7 Appendix 49
7.1 Bibliography 49
7.2 Abbreviations 54
7.3 Methodology 57
7.4 Forecasting Methodology 57
7.4.1 Diagnosed RA Patients 57
7.4.2 Percentage of Drug-Treated Patients 58
7.4.3 General Pricing Assumptions 58
7.4.4 Individual Drug Assumptions 60
7.4.5 Generic and Biosimilar Erosion 60
7.5 Primary Research – KOLs Interviewed for This Report 61
7.6 Primary Research – Prescriber Survey 63
7.7 About the Authors 64
7.7.1 Analyst 64
7.7.2 Reviewer 64
7.7.3 Therapy Area Director 64
7.7.4 Global Head of Healthcare 65
7.8 About GlobalData 66
7.9 Disclaimer 66

1.1 List of Tables
Table 1: Symptoms of RA 19
Table 2: 1987 ACR Diagnostic Criteria for RA 22
Table 3: 2010 ACR/EULAR Diagnostic Criteria for RA 23
Table 4: Treatment Guidelines for RA Used by Each Country in the 10MM 26
Table 5: ACR 2012 Criteria for RA Remission and Low/Moderate/High Disease Activity 29
Table 6: EULAR 2013 Criteria for RA Remission 30
Table 7: Most Prescribed Biologics for RA (After csDMARDs) in the Global Markets, 2014 34
Table 8: Leading Branded Treatments for RA 2014 41
Table 9: Product Profile - Remicade 44
Table 10: Remicade SWOT Analysis, 2014 47
Table 11: Global Sales Forecasts ($m) for Remicade, 2013-2023 48
Table 12: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 63

1.2 List of Figures
Figure 1: Normal Synovial Joint and Synovial Joint with RA 15
Figure 2: Cellular and Cytokine Targets for the Current RA Drugs 18
Figure 3: Disease Management Flowchart for Early RA - ACR 2012 30
Figure 4: Disease Management Flowchart for Established RA - ACR 2012 31
Figure 5: Flowchart for the Management of RA - EULAR 2013 32

[면책사항]
http://www.globalresearch.kr/disclaimer

★조사보고서 [Remicade (infliximab) (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023]에 관해서 E메일 문의 연락
◆H&I글로벌리서치의 고객기업(예)◆